An Open-label, Single-arm Study to Assess the Safety Tolerability of Cinacalcet in Addition to Standard of Care in Pediatric Subjects Age 28 Days to < 6 Yrs With Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Dialysis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 21 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cinacalcet (Primary)
Indications Renal failure; Secondary hyperparathyroidism
Focus Therapeutic Use
Sponsors Amgen

Most Recent Events

22 Jun 2016 Status changed from active, no longer recruiting to discontinued.
28 Apr 2016 Planned End Date changed from 1 Aug 2017 to 1 Jun 2016.
28 Apr 2016 Planned primary completion date changed from 1 Aug 2017 to 1 Jun 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight